Decreased expression of Klotho in cardiac atria biopsy samples from patients at higher risk of atherosclerotic cardiovascular disease

被引:0
|
作者
Giovanni Corsetti [1 ]
Evasio Pasini [2 ]
Tiziano M Scarabelli [3 ,4 ]
Claudia Romano [1 ]
Pratik R Agrawal [3 ]
Carol ChenScarabelli [5 ]
Richard Knight [4 ]
Louis Saravolatz [4 ]
Jagat Narula [3 ]
Mario FerrariVivaldi [6 ]
Vincenzo Flati [7 ]
Deodato Assanelli [8 ]
Francesco S Dioguardi [9 ]
机构
[1] Department of Clinical & Experimental Sciences,Division of Human Anatomy & Physiopathology,University of Brescia
[2] "SMaugeri Foundation",IRCCS,Cardiology Division,Medical Centre of Lumezzane
[3] Zena and Michael A,Wiener Cardiovascular Institute,Mount Sinai Medical Center
[4] Center for Heart and Vessel Preclinical Studies,StJohn Hospital & Medical Center,Wayne State University School of Medicine
[5] VA Ann Arbor Health Care System,University of Michigan
[6] Department of Cardiovascular Surgery,"San Rocco" Hospital
[7] Department of Biotechnological and Applied Clinical Sciences,University of L'Aquila
[8] Division of Sport-Internal Medicine,Department of Clinical & Experimental Sciences,University of Brescia
[9] Department of Clinical Sciences and Community Health,University of
关键词
D O I
暂无
中图分类号
R54 [心脏、血管(循环系)疾病];
学科分类号
摘要
Background Klotho proteins(α-and β) are membrane-based circulating proteins that regulate cell metabolism,as well as the lifespan modulating activity of Fibroblast Growth Factors(FGFs).Recent data has shown that higher plasma circulating Klotho levels reduce cardiovascular risk,suggesting Klotho has a protective role in cardiovascular diseases.However,although so far it has been identified in various organs,it is unknown whether cardiomyocytes express Klotho and FGFs,and whether high cardiovascular risk could affect cardiac expression of Klotho,FGFs and other molecules.Methods We selected 20 patients with an estimated 10-year high atherosclerotic cardiovascular disease and 10 age-matched control subjects with an estimated 10-year low risk undergone cardiac surgery for reasons other than coronary artery by-pass.In myocardial biopsies,we evaluated by immuno-histochemistry whether Klotho and FGFs were expressed in cardiomyocytes,and whether higher cardiovascular risk influenced the expression of other molecules involved in endoplasmic reticulum stress,oxidative stress,inflammation and fibrosis.Results Only cardiomyocytes of patients with a higher cardiovascular risk showed lower expression of Klotho,but higher expressions of FGFs.Furthermore,higher cardiovascular risk was associated with increased expression of oxidative and endoplasmic reticular stress,inflammation and fibrosis.Conclusions This study showed for the first time that Klotho proteins are expressed in human cardiomyocytes and that cardiac expression of Klotho is down-regulated in higher cardiovascular risk patients,while expression of stress-related molecules were significantly increased.
引用
收藏
页码:701 / 711
页数:11
相关论文
共 50 条
  • [31] Lipoprotein(a)-Associated Residual Atherosclerotic Cardiovascular Disease Risk in Patients with Cardiovascular Disease on Statin Therapy by Diabetes Status
    Zhao, Yanglu
    Sung, Jennifer C.
    Browne, Auris
    Wong, Nathan D.
    DIABETES, 2020, 69
  • [32] Rationale, Criteria, and Impact of Identifying Extreme Risk in Patients with Atherosclerotic Cardiovascular Disease
    Zeng, Yuhong
    Zhao, Dong
    CARDIOLOGY DISCOVERY, 2022, 2 (02): : 114 - 123
  • [33] Association of glucose to lymphocyte ratio with the risk of death in patients with atherosclerotic cardiovascular disease
    Lei, Jinglin
    Duan, Wentao
    Yao, Xiaoxi
    Hu, Zheng
    Fan, Huihui
    Liu, Yifan
    Zhong, Wenjian
    Li, Haipeng
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [34] A Machine Learning Approach to Simplify Risk Stratification of Patients with Atherosclerotic Cardiovascular Disease
    Li, Hsin Fang
    Nute, Andrew
    Weerasinghe, Roshanthi
    Wendt, Staci
    Wilson, Eleni
    Sidelnikov, Eduard
    Kathe, Niranjan
    Swihart, Charissa
    Jones, Laney
    Gluckman, Ty
    CIRCULATION, 2024, 150
  • [35] Therapy in patients at high risk for atherosclerotic cardiovascular disease -: From biological efficacy to disappointing clinical outcomes
    Fainaru, M
    FREE RADICAL BIOLOGY AND MEDICINE, 2002, 33 : S186 - S186
  • [36] Atherosclerotic cardiovascular disease and heart failure: Determinants of risk and outcomes in patients with diabetes
    Nelson, Adam J.
    Peterson, Eric D.
    Pagidipati, Neha J.
    PROGRESS IN CARDIOVASCULAR DISEASES, 2019, 62 (04) : 306 - 314
  • [37] Features and implications of higher systolic central than peripheral blood pressure in patients at very high risk of atherosclerotic cardiovascular disease
    Kim, Hyungseop
    Kim, In-Cheol
    Hwang, Jongmin
    Lee, Cheol Hyun
    Cho, Yun-Kyeong
    Park, Hyoung-Seob
    Chung, Jin-Wook
    Nam, Chang-Wook
    Han, Seongwook
    Hur, Seung-Ho
    JOURNAL OF HUMAN HYPERTENSION, 2021, 35 (11) : 994 - 1002
  • [38] RISK FACTORS PROFILE AND CONTROL IN PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: TIME TO ACT
    Burazor, Ivana
    Colic, Mirko
    Grujic, Stefan
    Otasevic, Petar
    Babic, Rade
    Bojic, Milovan
    Giga, Vojislav
    Kanjuh, Vladimir
    Florensa, Ana Marza
    Graham, Ian
    ATHEROSCLEROSIS, 2024, 395
  • [39] Features and implications of higher systolic central than peripheral blood pressure in patients at very high risk of atherosclerotic cardiovascular disease
    Hyungseop Kim
    In-Cheol Kim
    Jongmin Hwang
    Cheol Hyun Lee
    Yun-Kyeong Cho
    Hyoung-Seob Park
    Jin-Wook Chung
    Chang-Wook Nam
    Seongwook Han
    Seung-Ho Hur
    Journal of Human Hypertension, 2021, 35 : 994 - 1002
  • [40] The Veterans Affairs Cardiac Risk Score Recalibrating the Atherosclerotic Cardiovascular Disease Score for Applied Use
    Sussman, Jeremy B.
    Wiitala, Wyndy L.
    Zawistowski, Matthew
    Hofer, Timothy P.
    Bentley, Douglas
    Hayward, Rodney A.
    MEDICAL CARE, 2017, 55 (09) : 864 - 870